Exact Sciences Corporation (EXAS)
| Market Cap | 20.03B +131.2% |
| Revenue (ttm) | 3.25B +17.7% |
| Net Income | -207.95M |
| EPS | -1.10 |
| Shares Out | 190.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21,548,536 |
| Open | 104.93 |
| Previous Close | 103.92 |
| Day's Range | 104.90 - 104.98 |
| 52-Week Range | 38.81 - 104.98 |
| Beta | 1.44 |
| Analysts | Hold |
| Price Target | 86.62 (-17.43%) |
| Earnings Date | Apr 30, 2026 |
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients... [Read more]
Financial Performance
In 2025, Exact Sciences's revenue was $3.25 billion, an increase of 17.69% compared to the previous year's $2.76 billion. Losses were -$207.95 million, -79.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for EXAS stock is "Hold." The 12-month stock price target is $86.62, which is a decrease of -17.43% from the latest price.
News
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association fo...
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Aw...
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration
WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia He...
Exact Sciences Stockholders Approve Acquisition by Abbott
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted t...
Exact Sciences Announces Record Fourth Quarter and Full Year 2025 Results
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $878 million for...
Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences' '746 Patent
ST. LOUIS--(BUSINESS WIRE)--Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and A...
Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that esta...
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX B...
Exact Sciences Shareholders Unhappy With $105 Per Share Sale to Abbott Should Contact Julie & Holleman LLP Regarding Potential Claims
NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Julie & Holleman LLP, a top-tier shareholder rights firm, is investigating Abbott's proposed $21 billion acquisition of Exact Sciences Corp. (NASDAQ: EXAS)....
Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® ...
Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts across its Precision Oncology portfolio at t...
Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Exact...
Why the Stock Price of This Cancer Screening Company Soared 17% Thursday
Shares of cancer screening test maker Exact Sciences Corp. (EXAS) surged Thursday after Abbott Laboratories (ABT) announced a deal to acquire the company for about $21 billion.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Exact Sciences Corporation (Nasdaq – EXAS)
BALA CYNWYD, Pa., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Exact Sciences Corporation (“Exa...
Is it too late to buy Exact Sciences stock after Abbott's $21B deal?
Exact Sciences (NASDAQ: EXAS) rallied nearly 20% on November 20 after Abbott Laboratories (NYSE: ABT) announced a $21 billion all-cash deal to acquire the molecular diagnostics company.
Top Stock Movers Now: Walmart, Nvidia, Exact Sciences, Bath and Body Works, and More
Major U.S. equities indexes turned lower Thursday afternoon, reversing early gains as a rally powered by Nvidia's (NVDA) blockbuster earnings after the bell Wednesday faded. The Dow Jones Industrial A...
Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test
Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Abbott to Acquire Exact Sciences for $21 Billion
Abbott agreed to acquire Exact Sciences for $105 a share, representing a total equity value of about $21 billion.
Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.
Abbott Laboratories agrees to buy the cancer screening company in a cash deal.
Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences
Abbott said on Thursday it would buy cancer test maker Exact Sciences in an up to $23 billion deal, bolstering the medical device maker's diagnostics business.
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
Acquisition adds a new growth vertical to Abbott's already high single-digit growth profile, gaining leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics...
Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories
A report said the conglomerate Abbott Laboratories is close to a deal to acquire the company.
Abbott is weighing takeover of Exact Sciences, Bloomberg News reports
Medical device maker Abbott Laboratories is nearing a potential takeover of cancer test maker Exact Sciences Corp , Bloomberg News reported on Wednesday, citing people familiar with the matter.
Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome's Blood-Based Colorectal Cancer Screening Tests
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the expiration of the waiting period under the Hart-Sc...
Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced pivotal clinical validation results from the ALTUS stu...